Dr Susannah Murphy, Department of Psychiatry, University of Oxford, explains:
'The Experimental Medicine Industry Partnership (EMIP) is a fantastic opportunity for industry partners and researchers to work together to share expertise and maximise opportunities for developing improved psychiatric treatments. By offering tailored peer review and advice the EMIP will help to rapidly progress new treatments into clinical trials, bringing potential new, life changing treatments a step closer to improving the lives of patients.'
Professor Catherine Harmer, Department of Psychiatry, University of Oxford, said:
'It was fascinating to hear pressing questions from an industry perspective and to take part in discussions with other academics. The conversations have spearheaded many collaborations and have inspired us to develop our models in ways that can also work for industry and their requirements. I look forward to continued and future collaborations.'
50 representatives from 15 industry partners and 90 Oxford researchers with expertise in cognitive neuroscience, pharmacology treatment, lifestyle interventions, gut health and precision psychiatry, took part in the AIMday event in July 2021, .
Read more about this and other topics discussed during the event.
For more information about the Experimental Medicine and Industry Partnership (EMIP)
An Academic Industry Meeting Day (AIMday) is an innovative networking event that allows organisations external to the University of Oxford to set the agenda and gain academic perspective on industry challenges.
The event was developed through the National Institute for Health Research Oxford Health Biomedical Research Centre (a partnership between the University of Oxford and the Oxford Health NHS Foundation Trust).